| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6391874 | NOVARTIS | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Jul, 2017
(6 years ago) | |
| US6727256 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
| US8513262 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
| US6713485 | NOVARTIS | Heterocyclic compounds |
Sep, 2020
(3 years ago) | |
| US7157466 | NOVARTIS | Quinazoline ditosylate salt compounds |
Nov, 2021
(2 years ago) | |
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6828320 | NOVARTIS | Heterocyclic compounds |
Jul, 2017
(6 years ago) | |
Tykerb is owned by Novartis.
Tykerb contains Lapatinib Ditosylate.
Tykerb has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Tykerb are:
- US6828320
- US6391874
- US6727256
- US8513262
- US6713485
- US7157466
Tykerb was authorised for market use on 13 March, 2007.
Tykerb is available in tablet;oral dosage forms.
Tykerb can be used as treatment of patients with breast cancer whose tumors overexpress the her2 receptor, treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including anthracycline, a taxane and trastuzumab.
Drug patent challenges can be filed against Tykerb from 14 March, 2011.
The generics of Tykerb are possible to be released after 18 September, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-235) | Dec 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
| New Indication(I-620) | Jan 29, 2013 |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Treatment: Treatment of patients with breast cancer whose tumors overexpress the her2 receptor; Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received...
Dosage: TABLET;ORAL
TYKERB family patents
